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Key points:   
• Sibship affects dispensing patterns, measured as incidence and persistence, of asthma 
medication in young children regardless of asthma diagnoses. 
• The estimated proportion of children with persistent asthma medication was lower for 
children with siblings compared with singletons, and there was no difference in effect 
between older, younger, full, half, or number of siblings.  
• When including the siblings’ dispensed asthma medication in the analysis and comparing 
with unrelated control children, the estimated proportion of children with persistent 
medication increased, suggesting that siblings may share asthma medications.  
Word count: 3,529 
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Abstract  
Purpose 
Our aim was to study the association between sibship and dispensing patterns of asthma 
medication in young children, focusing on incidence and persistence, and taking sibship status, 
asthma diagnoses, and siblings’ medication into account.     
Methods 
A register-based cohort study including all children (n=50,546) born in Stockholm, Sweden 
2006–2007, followed up during 2006–2014. Exposure was sibling status; outcome was incidence 
of dispensed asthma medication and persistence over time. A Cox-model was used to study the 
association between sibship and asthma medication. Persistence was defined using two different 
time windows (4- and 18-months) in a refill sequence model including siblings’ and unrelated 
control children’s medication.  
Results 
After one year of age, the adjusted hazard ratio of dispensed asthma medication was 0.85 (95%CI 
0.80–0.90) among children with siblings compared to singletons. The estimated proportion of 
children with persistent controller medication was 7.2% (4-month model) and 64.5% (18-month 
model). When including the siblings’ controller medication, the estimated proportion was 8.8% 
(4-months) and 7.8% for control children (relative risk, RR 0.89, 95%CI 0.81-0.98). The 
persistence was lower for those with siblings compared to singletons (adj. RR 0.72, 95%CI 0.62-
0.85 for 4-months) with similar estimates for older, younger, and full siblings and regardless of 
asthma diagnoses. 
Conclusions 
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Siblings have different dispensing patterns of asthma medications compared to singletons 
regardless of asthma diagnoses. After including the siblings’ asthma medication and compared 
with control children, the proportion of children with persistent medication increased which may 
indicate that siblings share asthma medications. 
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Introduction 
Asthma is one of the most common chronic diseases among children worldwide, and as many as 
one out of five children have experienced asthma symptoms up to age 12 (1, 2). Pharmacological 
treatment is a cornerstone in asthma management and many studies have shown room for 
improvement in adherence to medication and guidelines (3-5), although some have limitations 
such as cross-sectional design or small samples of patients collected through surveys, sometimes 
with poor response-rates (e.g., (6-11). To achieve asthma control, continuous use of controller 
medication is required for many children with asthma (1). However, the need for asthma 
medication can vary over time, due to viral infections or exposure to allergens, which in turn 
leads to irregular dispensing patterns of asthma medications.  
Having an older sibling is associated with a lower risk of asthma (12-14). This may be due to an 
increased risk of infections during childhood which may reduce the risk of asthma and allergic 
disease (15). It may also be explained by differences in parental health-seeking behavior in first-
born children compared to younger siblings (14). Sibling status, i.e., being singleton, full- or half 
sibling, can also be associated with differences in children’s medication dispensing and use, such 
as sharing medication, i.e. the lending or borrowing of prescribed medications (16). In a 
systematic review by Beyene et al., it was found that sharing of medication was common (17), 
with a prevalence of 6-23% for lending medication and 5-52% for borrowing. Sharing of asthma 
medication has been addressed in a few studies (18-22), but only two studies have addressed 
sharing among children and adolescents (21, 22) or the effect on family income (21). In a 
previous study, we found that 13% of the adolescents with asthma claimed that they used 
someone else’s medication (23). However, it is still unknown to what extent sibship influences 
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dispensing patterns of medications and if there is any difference among children with older, 
younger, and full- and half siblings. 
In registers, continuous medication use is often measured as persistence (24-26), i.e., time from 
initiation to discontinuation of treatment (26). Although registers are considered as the golden 
standard when measuring persistence, there is no standard method on how to measure persistence 
in children with asthma since the need for asthma medication can vary over time due to infections 
or allergen exposure. We previously showed that different time windows in a register influenced 
the prevalence of asthma medication (7)  but the impact of different time windows on the 
estimated persistence has not been studied. Using a time window of 12 months, Øymar et al. 
found that the prevalence of inhaled corticosteroids (ICS) among pre-school children was high, 
but the persistence was low. (27). Furthermore, no study has, to the best of our knowledge, 
included the siblings’ medication in a persistence model, or accounted for sibship status (older, 
younger, full, half and number of siblings). Better understanding may inform healthcare 
professionals seeing children with asthma and improve clinical care. Based on clinical experience 
and previous studies (12-14, 16, 23) on medication sharing, our hypothesis is that siblings have 
different dispensing patterns of asthma medications compared to singletons, and that this also 
depends on sibship status, and diagnoses.     
The aim of this study was to assess the association between sibship and dispensing patterns of 
asthma medications in young children. Focus was on a) initiation of asthma medication, and b) 
differences in persistence of the drug therapy, taking sibship status, diagnoses, and siblings’ 
asthma medications into account.  
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Methods 
Study design and study population 
This was a population-based cohort study including all children born in Stockholm County, 
Sweden, between January 1, 2006 and December 31, 2007. This period was selected since the 
Swedish Prescribed Drug Register (SPDR) started on July 1, 2005, and we wanted to include 
information on all dispensed medications from birth onwards. Information on siblings was 
included, and those born in 2006 or 2007 contributed as study participants as well as siblings. 
The study period ranged from January 1, 2006 to December 31, 2014.  
The children were identified from the Medical Birth Register (MBR) (28) and linked to the Multi 
Generation Register (MGR) (29), using each child’s personal identity number (PIN). The full- 
and half siblings were identified from their biological mothers and fathers in the MGR, as well as 
older and younger siblings. Area of residence from Statistics Sweden provided information about 
emigration from the Stockholm County. The date of death from the Cause of Death register was 
also collected. The SPDR was added to the data to obtain information on dispensed prescription 
medications for each child and his or her siblings (30). The children’s diagnoses were retrieved 
from the National Patient Register (NPR) (31) and the administrative healthcare databases VAL 
held by the Stockholm County Council (32). Finally, the socioeconomic status (family income) 
was collected from the longitudinal integration database for health insurance and labor market 
studies (LISA by Swedish acronym), held by Statistics Sweden (29). All data was linked using 
the children’s personal identity number. 
Exposure 
Each child’s sibling status was used as the exposure and defined in five different ways; a) no 
sibling/sibling, b) no sibling/older/younger/both older and younger, c) no sibling/full/half/both 
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full and half, d) no sibling/one sibling/at least two siblings, and e) no sibling/sibling without an 
asthma diagnosis/sibling with an asthma diagnosis. The sibling status was updated yearly during 
the follow-up. 
Siblings’ asthma diagnosis was denoted if at least one of the siblings had a recorded diagnosis of 
ICD-10 J45 or J46 from inpatient care, specialized ambulatory care, or primary care.  
 
Outcome 
Dispensed asthma medication was used as the outcome, identified by ATC-codes as: Short-acting 
β2-agonists, SABA (ATC-codes R03AC02, R03AC03); Inhaled corticosteroids, ICS (R03BA); 
Leukotriene receptor antagonists, LTRAs (R03DC); Long-acting β2-agonists, LABA (R03AC12, 
R03AC13); Fixed combination of ICS + LABA (R03AK); at least one of SABA, ICS, LTRAs, 
LABA, or fixed combination was denoted as ‘any asthma medication.’  
Persistence after 1.5 years was defined as refill of a prescription with a controller medication 
(either ICS, LTRAs, or fixed combination) within a defined time window (4- or 18-months). In 
the sibling persistence model, the child was classified as being persistent to controller medication 
if the child or his/her sibling refilled the prescription within the defined time window (Figure 1).  
 
Potential confounders 
The child’s sex was collected from the MBR. Family income was collected from the LISA 
database and defined as disposable income at the household level during 2006. Disposable 
income includes individual net benefits after deduction of debits such as taxes, repaid study 
allowance, and paid maintenance support. The family income was divided into quartiles.  
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Asthma diagnosis among index children was defined as any recorded diagnosis (main or 
contributing diagnosis) of ICD-10 J45 or J46 from inpatient care, specialized ambulatory care, or 
primary care (33). 
Parental diagnosis of asthma was denoted if at least one of the parents had a recorded diagnosis 
of ICD-10 J45 or J46 from inpatient care, specialized ambulatory care, or primary care. 
 
Statistical analyses 
Descriptive statistics including frequencies, proportions, and quartiles were used to describe the 
study population. The prevalence of asthma medication and asthma diagnosis was calculated as 
the number of children with dispensed medication/recorded diagnosis during the follow-up, 
divided by all the children in the study population. We calculated unadjusted incidence rates for 
first asthma medication dispensed as the number of first dispenses per 1000 person-years with 
95% confidence intervals (CIs) based on the Poisson distribution.  
A Cox-model, with age as time scale, was used to study the association between sibship and 
initiation of asthma medication. Hazard ratios (HR) with 95% CIs were estimated. Sibship was 
used as a time-varying exposure. The Cox-model was adjusted for family income. A child was 
censored when moving from Stockholm County, death, or end of follow-up (December 31, 
2014), whichever occurred first. Due to non-proportional hazards, an interaction term with age 
was included (below/above age 1 year).  
Persistence was defined with two different time windows, 4- and 18-months, using a refill 
sequence model (25). The 4-month time window was selected based on the Swedish 
reimbursement system, where a prescription for medication for a chronic disease is normally 
refilled after 3 months. The 18-month time window was used based on our previous findings (7). 
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To be classified as being persistent to asthma controller medication, the prescription had to be 
refilled within the defined time window (4- or 18-months), see Figure 1. Sibship was assessed at 
the time of initiation of controller medication. The estimated proportion of children with 
persistent asthma controller medication was measured as percentage with 95% CI. In addition, 
siblings’ controller medication was added to a sibling persistence model, in which the child was 
classified as being persistent if the child or his/her sibling refilled the prescription within the 
defined time window. However, adding another child’s medication to the persistence evaluation 
would automatically increase the persistence. Therefore, for comparison, we added controller 
medication from randomly selected siblings in the cohort to an unrelated control child’s 
persistence model, in which the index child and the assigned control child’s controller medication 
was included. Only children who live together (at least part time) i.e. siblings, would have the 
chance to share medication. Thus, the persistence model including asthma medication from the 
unrelated control children was compared to the sibling persistence model to test the difference in 
persistence. A significant higher persistence in the sibling model compared to the unrelated 
control children model would suggest that siblings share medications. A log-binomial regression 
model was used to estimate the relative risk (RR) with 95% CIs for the association between 
sibship and persistence of asthma medication after 1.5 years, using both the 4-month and 18-
month models. The models were adjusted for family income. Asthma diagnosis and parental 
asthma diagnosis were added to the model as interaction terms with sibship and tested for with 
the Likelihood ratio test.  
>>>Insert Figure 1 here<<< 
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Results 
The study population consisted of 50 546 children with 9% censored during follow-up, due to 
moving from Stockholm County (n=4501) or death (n=48). At birth, 59% of the children had an 
older sibling (43% full sibling, 10% half sibling, and 6% both full and half siblings) in the whole 
study population. Among children in the persistence analysis, the proportion of children with 
older siblings at birth was 72% (n=8567); Table 1.  
<<<Insert Table 1 here<<< 
In total, 23% of the study population was dispensed asthma medication (27% of the boys and 
20% of the girls). Controller medication was dispensed to 19% of the study population, and 15% 
of the study population had both an asthma diagnosis and a controller medication. The mean age 
of the first dispensed asthma controller medication was 2.13 years (CI 2.10-2.17) and the mean 
age of recorded asthma diagnosis was 2.39 years (CI 2.34-2.43) among children in the 4-months 
persistence model.  
Incidence of asthma medication 
The incidence rate of dispensed asthma medication in the first year of life was higher for children 
with siblings (81.2 per 1000 person-years) than for those without siblings (34.1 per 1000 person-
years) (Table 2). The incidence rate was higher regardless of whether the sibling was older, 
younger, full or half. The adjusted hazard ratio for being dispensed asthma medication was 2.37 
(95% CI 2.15–2.60) in the first year of life for children with siblings compared to children 
without siblings. After one year of age, the incidence rate of being dispensed asthma medication 
was lower for children with siblings (27.2 per 1000 person-years) than for singletons (49.5). The 
adjusted hazard ratio for dispensed asthma medication was 0.85 (95% CI 0.80–0.90) for those 
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with siblings compared to those without. The hazard ratios were similar for children with older, 
younger, and full siblings but not for those with half siblings.  
>>>Insert Table 2 here<<< 
Persistence of asthma medication 
The estimated proportion of children with persistent asthma controller medication differed 
between the time windows. The estimated proportion after 1.5 years was 7.2% (95% CI 6.6–7.7) 
for the 4-month time window and 64.5% (95% CI 63.5–65.4) for the 18-month time window 
(Table 3). Among index children with a doctor’s diagnosis of asthma, the estimated proportion of 
children with persistent asthma controller medication was 8.2% (95% CI 7.5–9.0) and 72.1% 
(95% CI 71.3–73.1), respectively. After including their siblings’ controller medication dispensing 
data in the analysis, the estimated proportion was 8.8% (95% CI 8.2–9.4) with the 4-month time 
window and 73.6% (95% CI 72.6-74.5) with the 18-month time window. In the sibling 
persistence model, a total of 80,536 controller medication prescriptions were included of which 
16,897 (21%) originated from the siblings. In the persistence model including controller 
medication from unrelated control children, the corresponding proportion of persistence was 
7.8% (95% CI 7.3–8.4) and 72.6 (95% CI 71.7–73.6) respectively. 
>>>Insert Table 3<<< 
The estimated proportion of children with persistent asthma controller medication after 1.5 years 
was lower among those with siblings compared to those without (adj. RR 0.72, 95%CI 0.62-0.85 
with the 4-month model; Table 4). Children with younger siblings had the lowest proportion of 
persistence to asthma controller medication. There was no significant difference in the proportion 
between children with half-siblings and singletons, when using the 4-month time window. 
Furthermore, the estimated proportion was not affected by the number of sibling or if the siblings 
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had an asthma diagnosis. The estimated proportion of children with persistent controller 
medication was lower for the model including medication from an unrelated control child than 
that including medication of siblings, RR 0.89 (95% CI 0.81–0.98) with the 4-month time 
window but there was no statistical difference for the 18-month time window, RR 0.99 (95% CI 
0.97–1.00).  
>>>Insert Table 4 here<<< 
The association between sibling status and persistence medication was not affected by sex, 
asthma diagnosis of the index child, and parental asthma (p>0.1; data not shown). 
Discussion 
In this population-based cohort study of all children born in Stockholm County during 2006-
2007, the incidence of dispensed asthma medication was lower among children with siblings 
compared to singletons after the first year of life. In general, the estimated proportion of children 
with persistent asthma controller medication was lower among children with siblings compared 
to singletons.  
Children with siblings, in particular older and full siblings, were more likely to be dispensed 
asthma medication in the first year of life compared to singletons. The reason for this may be that 
older siblings transmit respiratory tract infections, which, in turn, increases the risk of viral-
induced asthma. After the first year, children with siblings received less asthma medication. One 
explanation could be that older children are more likely to develop asthma, whereas having an 
older sibling decreases the risk of developing asthma (12-14, 34). Another explanation could be 
that in families with several children, parents have less time to dispense and administer the 
child’s medication (35). On the other hand, parents’ positive attitude toward their child’s asthma 
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medication has been found to be associated with good adherence (36), which in turn would 
increase the dispensing of asthma medication. Children with only half siblings had a risk similar 
to singletons of having had asthma medication dispensed. This might be because half siblings 
live in separate homes, at least part time, and are therefore less exposed to each other, or they do 
not have full access to their half siblings’ supply of asthma medication (37).    
The estimated proportion of children with persistent controller medication differed largely with 
different time windows. The reason for this is most likely the irregular dispensing patterns for 
children with asthma, which has also been seen in other studies (27). Few children had their 
prescriptions refilled after four months, which is not surprising since asthma in young children is 
often an intermittent disease (10). The estimated proportion of children with persistent 
medication after 18-months was quite high, which is in accordance with one of our previous 
studies (7). One explanation for the lower proportion of children with persistent medication 
among those with siblings could be that siblings share medications. Also, when including the 
siblings’ controller medication in the model, the estimated proportion after 1.5 years was slightly 
higher and statistically different from the estimated proportion when including medication of an 
unrelated control child using the 4-month time window. Only children who live together (at least 
part time) i.e. siblings, would have the chance to share medication. However, when using the 18-
month model, the differences were smaller and non-significant. Furthermore, the estimated 
proportion of children with persistent medications was lower among children with younger 
siblings compared to older siblings. Having a younger sibling may change the family situation at 
home including having less time to refill prescriptions of asthma medications.  
To our knowledge, this is the first study on incidence and persistence of asthma medications in 
relation to sibship, diagnoses and siblings’ medications. Øymar et al. calculated the incidence of 
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ICS each year (27) and found that the incidence was highest the second year of life and decreased 
each year up to year 5. They also found a low proportion of pre-school children with persistent 
ICS; only 9–18% refilled a prescription of ICS every 12 months after 5 years. In a review by 
Desai and Oppenheimer, it was concluded that non-adherence (not taking medication as agreed) 
among children with asthma was alarmingly high (35). Among children with intermittent asthma, 
admitted to the Children’s Hospital of Michigan, Detroit, 25% lacked asthma medication (38). 
That corresponds to our estimated proportion of children with persistent medication of 72% 
among those with an asthma diagnosis, using the 18-month time window. In a Dutch study, 88% 
of the children (aged 7–17 years) were dispensed at least one ICS prescription during a 12-month 
period. However, only half of them used more than one inhalation of ICS per day (36), indicating 
non-adherence. This can also be an explanation for our results with a low proportion of children 
with persistent medication using the 4-month time window and a substantial increase in the 
proportion with the 18-month time window. We also found that the number of siblings and 
diagnosis of asthma in the index child, sibling or parent did not affect the estimated proportion of 
children with persistent medication. A potential explanation could be that sharing asthma 
medications can be mutual, i.e. the index children could either lend or borrow medication from 
their sibling, although this would not be the case for parents due to different devices used for 
inhalation in different age-groups. In a previous study, we found that 10% of the adolescents with 
asthma reported use of someone else’s medication (23). The lack of impact of asthma diagnosis 
may be due to treatment with asthma medication without getting a diagnosis (32, 33). 
Our main findings remained after adjusting for family income. However, Gong et al., found the 
lowest incidence of dispensed asthma medication among young children in Sweden from the 
lowest income families (39).  
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As far as we know, no other study has included both the children and their siblings’ asthma 
medication in the same persistence model. The sibling model might be more complete and may 
suggest that the proportion of children with persistent controller medication is not as low as 
previously shown (27, 35). Excluding siblings’ asthma medications from persistence models 
when using dispensing data from pharmacies may underestimate the actual persistence among 
children with siblings. However, more research is needed to explore the association between 
sibship and dispensing patterns. Healthcare professionals seeing children with asthma should be 
aware of the possibility of sharing medications among siblings and be sure to take a thorough 
medical history. Furthermore, it is important for healthcare professionals meeting families with 
asthmatic children, to stress that treatment and choice of devices needs to be individualized. 
Every child should have an individual treatment plan and a sufficient medical supply tailored for 
his/her need.   
 
Strengths and limitation 
This was a register-based cohort study including all children born in an entire region. The high 
quality of the data made it possible to follow all children’s and their siblings’ medication, 
allowing for a complete persistence model. We also had full information on recorded diagnoses 
from inpatient, specialized and ambulatory care over time.  
The main limitations are those associated with registries. Even though we had data on all 
dispensed prescriptions both for the children in the study population and their siblings, we do not 
know if the siblings actually shared medications. Longitudinal analyses of dispensing data are 
considered the golden standard when measuring persistence of medication (26), still it is 
important to emphasize that dispensing a prescription is not necessarily equal to use of 
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medication. Also, children classified as being non-persistent may have grown out of their asthma 
and is it not possible to distinguish different types of asthma. However, when using the 18-month 
time window the persistence increased substantially, suggesting that the majority of children 
needs asthma controller medication i.e., either still has asthma symptoms at least intermittently or 
use medication to avoid them.  
 
In conclusion, we confirm our hypothesis that siblings compared to singletons have different 
dispensing patterns of asthma medications. These differences were seen regardless of asthma 
diagnoses. Also, after taking the siblings’ asthma medication into account, and comparing with 
unrelated control children, the proportion of children with persistent medication increased, which 
may indicate that siblings share asthma medications. 
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Figure legends 
Figure 1: Persistence model for hypothetical children with two different time windows (4- and 18-
months). Persistence was defined as refilling the prescription of controller medication (ICS, LTRA, or fixed 
combination) within the defined time window.  
 
 
Table 1: Characteristics of the study population and the children in the persistence analysis. 
Characteristics All children in the study 
population (N=50,546) 
Children in the persistence 
analysis (n=8,567)1 
Boys 51% (26,014) 59% (5,091) 
  Sibship status at birth   
No siblings 41% (20,675) 28% (2,378) 
Older siblings 59% (29,857) 56% (4,758) 
Younger siblings 0 11% (955) 
Both older and younger siblings 0 6% (476) 
Full sibling  43% (21,685) 54% (4,588) 
Half sibling 10% (5,060) 9% (804) 
Both full and half sibling 6% (3,126) 9% (797) 
  Family income2 
Q1 
Q2 
Q3 
Q4 
 
SEK3 0 – 211,800  
SEK 211,801 – 345,900  
SEK 345,901 – 474,700  
SEK 474,701 – 7.18*107 
 
SEK 0 – 213,100  
SEK 213,001 – 343,000  
SEK 343,001 – 466,600 
SEK 466,601 – 7.18 *107 
1. Children with a dispensed controller medication (ICS, fixed combination of ICS and LABA or LTRA). 
2. Disposable income (individual net benefits after deduction of debits such as taxes, repaid study 
allowance and paid maintenance support) at household level during 2006.  
3. Foreign exchange rate: 100 SEK = 11.85 USD. 
 
Table 2: Incidence rates and hazard ratio (HR) with 95% confidence intervals (CI) of dispensed asthma 
medication and sibship status using a cox model. 
Sibship Incidence rates/ 1000 
person-years (CI) 
Person-years Crude HR (CI) Adj.* HR (CI) 
Age 0-1     
No sibling (ref) 
 
34.1 (31.6-36.7) 19 895 1 1 
Sibling  
 
81.2 (77.9-84.5) 28 896 2.39 (2.20-2.61) 2.37 (2.15-2.60) 
Older sibling 80.9 (77.7-84.3) 28 277 2.39 (2.19-2.60) 2.36 (2.14-2.59) 
Younger sibling 61.8 (38.4-99.4) 275 1.77 (1.10-2.87) 2.25 (1.29-3.93) 
Both older & younger 
sibling 
 
113.4 (82.9-155.2) 343 3.34 (2.43-4.60) 3.43 (2.31-5.09) 
Full sibling 85.2 (81.3-89.3) 20 521 2.51 (2.30-2.75) 2.48 (2.24-2.74) 
Half sibling 50.4 (44.5-57.2) 4 838 1.48 (1.28-1.71) 1.52 (1.30-1.79) 
Both full & half sibling 99.1 (89.3-110.1) 3 551 2.92 (2.56-3.32) 3.21 (2.77-3.72) 
     
Age 1-6     
No sibling (ref) 
 
49.5 (47.5-51.5)) 46 896 1 1 
Sibling  
 
27.2 (26.5-27.9) 225 073 0.85 (0.81-0.90) 0.85 (0.80-0.90) 
Older sibling 31.3 (30.4-32.3) 127 560 0.84 (0.80-0.89) 0.84 (0.79-0.89) 
Younger sibling 22.5 (21.3-23.7) 64 956 0.91 (0.85-0-98) 0.90 (0.83-0.98) 
Both older & younger 
sibling 
 
20.3 (18.8-21.9) 32 558 0.82 (0.75-0.90) 0.80 (0.73-0.89) 
Full sibling 29.3 (28.2-30.4) 96 279 0.80 (0.75-0.84) 0.79 (0.74-0.84) 
Half sibling 41.7 (38.8-44.8) 17 889 1.05 (0.97-1.14) 1.04 (0.95-1.14) 
Both full & half sibling 23.0 (22.1-23.9) 110 966 0.88 (0.83-0.93) 0.87 (0.81-0.93) 
*Adjusted for family income i.e. disposable income (individual net benefits after deduction of debits 
such as taxes, repaid study allowance and paid maintenance support) at household level during 2006. 
 
Table 3: The estimated proportion of children with persistent asthma controller medication after 1.5 
years in the different persistence models measured as % with 95% confidence intervals (CI), n=8,567. 
Persistence models 4-month 
model, % (CI) 
18-month 
model, % (CI) 
Index child’s controller medication 7.2 (6.6-7.7) 64.5 (63.5-65.4) 
Index child’s controller medication + asthma diagnosis 8.2 (7.5-9.0) 72.1 (71.3-73.1) 
Index child’s + siblings’ controller medication 8.8 (8.2-9.4) 73.6 (72.6-74.5) 
Index child’s + unrelated control child’s controller medication 7.8 (7.3-8.4) 72.6 (71.7-73.6) 
Table 4: Association between sibship status and controller medication persistence after 1.5 years with the 4 and 18 months’ models measured as   
proportions (%), relative risks (RR), and 95% confidence intervals (CI), n=8,567. 
Sibship 4m % Persistent (CI) 4m Crude RR (CI) 4m Adj.* RR CI) 18m % Persistent (CI) 18m Crude RR (CI) 18m Adj.* RR (CI) 
No sibling (ref) 8.7 (7.6-9.9) 1 1 71.1 (69.3-72.9) 1 1 
Sibling 6.6 (6.0-7.2) 0.76 (0.65-0.89) 0.72 (0.62-0.85) 62.1 (60.9-63.2) 0.87 (0.85-0.90) 0.87 (0.84-0.90) 
       
Older sibling 7.0 (6.3-7.8) 0.81 (0.69-0.96) 0.77 (0.65-0.92) 65.9 (64.6-67.2) 0.93 (0.90-0.96) 0.92 (0.89-0.95) 
Younger sibling 4.7 (3.5-6.3) 0.54 (0.40-0.74) 0.53 (0.39-0.73) 51.1 (48.2-54.0) 0.72 (0.68-0.76) 0.72 (0.67-0.76) 
Both older & younger sibling 5.7 (3.8-8.2) 0.65 (0.44-0.97) 0.63 (0.43-0.93) 50.5 (46.4-54.6) 0.71 (0.65-0.77) 0.71 (0.65-0.77) 
       
Full sibling 6.5 (5.8-7.3) 0.75 (0.64-0.89) 0.71 (0.59-0.84) 61.3 (59.9-62.6) 0.86 (0.83-0.89) 0.85 (0.83-0.88) 
Half sibling 7.8 (6.1-9.9) 0.90 (0.69-1.19) 0.93 (0.71-1.22) 64.4 (61.1-67.6) 0.91 (0.86-0.96) 0.91 (0.86-0.96) 
Both full & half sibling 
 
Number of siblings 1 
                                   2 
 
Siblings no asthma diagnosis 
Siblings with asthma diagnosis                                    
                                    
5.5 (4.0-7.3) 
 
6.9 (6.1-7.7) 
6.2 (5.3-7.2) 
 
6.5 (5.9-7.3) 
6.7 (5.5-8.0) 
0.64 (0.46-0.87) 
 
0.79 (0.66-0.94) 
0.71 (0.58-0.87) 
 
0.76 (0.64-0.90) 
0.77 (0.61-0.96) 
0.62 (0.45-0.84) 
 
0.75 (0.63-0.90) 
0.68 (0.56-0.83) 
 
0.72 (0.61-0.86) 
0.73 (0.58-0.92) 
64.1 (60.9-67.3) 
 
62.3 (60.8-63.8) 
61.7 (59.8-63.5) 
 
62.0 (60.6-63.3) 
62.3 (60.1-64.4) 
0.90 (0.85-0.95) 
 
0.88 (0.85-0.91) 
0.87 (0.83-0.90) 
 
0.87 (0.84-0.90) 
0.88 (0.84-0.91) 
0.90 (0.85-0.95) 
 
0.87 (0.84-0.90) 
0.86 (0.83-0.90) 
 
0.87 (0.84-0.90) 
0.87 (0.83-0.01) 
 
* Adjusted for family income i.e. disposable income (individual net benefits after deduction of debits such as taxes, repaid study allowance and paid 
maintenance support) at household level during 2006. 

